Literature DB >> 10837487

Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin.

M J Shapiro1, E J Weiss, T R Faruqi, S R Coughlin.   

Abstract

Protease-activated receptors 1 and 4 (PAR1 and PAR4) mediate thrombin signaling in human platelets. Whether these receptors are redundant, interact, or serve only partially overlapping functions is unknown. We report that PAR1 and PAR4 signal with distinct tempos. In transfected fibroblasts, PAR4 triggered substantially more phosphoinositide hydrolysis per activated receptor than PAR1 and was shut off more slowly than PAR1. Shutoff and internalization of PAR1 depends upon phosphorylation of its carboxyl tail upon receptor activation. In contrast to PAR1, phosphorylation of PAR4 was undetectable, and activation-dependent internalization of PAR4 was much slower than that seen for PAR1. Mutation of potential phosphorylation sites in the carboxyl tail of PAR1 enhanced PAR1 signaling, whereas analogous mutations in PAR4 had no effect. Thus PAR4 signaling is shut off less rapidly than PAR1, probably due to differences in receptor phosphorylation. PAR1 and PAR4 also signaled with distinct tempos in platelets. PAR1 triggered a rapid and transient increase in intracellular calcium, whereas PAR4 triggered a more prolonged response. Together, the tempo of these responses accounted for that triggered by thrombin. Thus differences in the rates at which PAR1 and PAR4 are shut off allow thrombin to trigger intracellular signaling with distinct temporal characteristics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837487     DOI: 10.1074/jbc.M004589200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

Review 1.  Targeting proteinase-activated receptors: therapeutic potential and challenges.

Authors:  Rithwik Ramachandran; Farshid Noorbakhsh; Kathryn Defea; Morley D Hollenberg
Journal:  Nat Rev Drug Discov       Date:  2012-01-03       Impact factor: 84.694

Review 2.  Signal transduction by protease-activated receptors.

Authors:  Unice J K Soh; Michael R Dores; Buxin Chen; JoAnn Trejo
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

3.  Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.

Authors:  Li Ma; Rafael Perini; Webb McKnight; Michael Dicay; Andre Klein; Morley D Hollenberg; John L Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-22       Impact factor: 11.205

Review 4.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 5.  Proteases display biased agonism at protease-activated receptors: location matters!

Authors:  Angela Russo; Unice J K Soh; JoAnn Trejo
Journal:  Mol Interv       Date:  2009-04

6.  Protease-Mediated Suppression of DRG Neuron Excitability by Commensal Bacteria.

Authors:  Jessica L Sessenwein; Corey C Baker; Sabindra Pradhananga; Megan E Maitland; Elaine O Petrof; Emma Allen-Vercoe; Curtis Noordhof; David E Reed; Stephen J Vanner; Alan E Lomax
Journal:  J Neurosci       Date:  2017-10-31       Impact factor: 6.167

7.  The chemistry and pharmacology of privileged pyrroloquinazolines.

Authors:  Bo Chao; Bingbing X Li; Xiangshu Xiao
Journal:  Medchemcomm       Date:  2015-04-01       Impact factor: 3.597

8.  Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents.

Authors:  Steeve Houle; Martin D Papez; Mara Ferazzini; Morley D Hollenberg; Nathalie Vergnolle
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

9.  Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice.

Authors:  Yingying Mao; Ming Zhang; Ronald F Tuma; Satya P Kunapuli
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

10.  Protease-activated receptors in cancer: A systematic review.

Authors:  Na Han; Ketao Jin; Kuifeng He; Jiang Cao; Lisong Teng
Journal:  Oncol Lett       Date:  2011-04-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.